Background: Hepatitis B virus (HBV) and tuberculosis (TB) represent major public health problems. There is currently little data on HBV infection among TB patients with and without human immunodeficiency virus (HIV). Objectives: To assess HBV prevalence among TB patients with and without HIV. Study design: From April 2008 to March 2010, a cross-sectional study was conduct among TB patients attended at a reference hospital in Goiânia City, Brazil. The participants were tested for serological markers of HBV infection and HIV antibodies. HBV DNA was detected in HBsAg-positive samples, and also in HBsAg-negative/anti-HBc-positive samples to look for HBV occult infection. Results: Of 425 patients, 402 (94.6%) agreed to participate in the study. The overall prevalence of HBV (HBsAg and/or anti-HBc positive) and HIV infections were 25.6% (103/402) and 27.6% (111/402), respectively. A higher HBV infection rate was found among HIV-infected patients (36.9%; 41/111) compared to patients infected with TB only (20.0%; 57/285). A multivariate analysis of risk factors showed that age ≥50 years (p = 0.03), non-injecting (p < 0.01) and injecting (p < 0.01) drugs use were associated with HBV infection. Among the HBsAg-positive samples (n = 13), HBV DNA was detected in 10 (76.9%) samples. Of the 90 anti-HBc-positive samples, 13 were HBV DNA positive (with very low levels) resulting in an occult HBV infection rate of 14.4%. PCR-RFLP was successfully performed in 20 HBV DNA-positive samples: 15 were genotype A and 5 were genotype D. Conclusions: HBV infection was common, particularly among this with HIV infection.
Background
Hepatitis B virus (HBV) remains a major cause of liver disease worldwide despite vaccination programs implemented over the last decade. Worldwide, it is estimated that 2 billion people are infected with HBV and that more than 350 million are chronically infected. Patients with chronic hepatitis B are at risk for developing liver cirrhosis and hepatocellular carcinoma. 1 In high prevalence areas, most HBV infection is acquired during the perinatal period or early in childhood. In contrast, in intermediate to low endemic areas, this infection occurs mainly in young adults and is disseminated either by parenteral or sexual transmission. 2 HBV infection is diagnosed commonly by the presence of hepatitis B surface antigen (HBsAg), which is indicative of acute or chronic infection. HBV DNA has, however, been detected in the liver and/or blood of individuals without detectable HBsAg. This condition is called occult HBV infection and its prevalence varies significantly between geographic regions as well as between populations. In terms of public health, the clinical importance of occult HBV infection arises from the risk of HBV transmission despite the low levels of HBV DNA. 3, 4 Based on an intergroup divergence of complete nucleotide sequences of 7.5% or greater, HBV has been classified into eight genotypes (A-H), which have a characteristic geographic distribution. 5 Tuberculosis (TB) is still among the most life-threatening infectious diseases, resulting in high mortality rates in adults. According to the World Health Organization, the estimate of the global burden of TB in 2010 was 8.8 million incident cases (range, 8.5-9.2 million) and 12 million prevalent cases (range, 11-14 million). 6 In Brazil, approximately 63 million people are infected with the TB bacilli with approximately 71,000 new cases reported every year, resulting in 4600 yearly deaths. 7 Human immunodeficiency virus (HIV) is the most significant risk factor associated with acquiring TB disease in those with latent or newly acquired Mycobacterium tuberculosis infections. 6 Moreover, HIV and/or HBV co-infections increase the risk of anti-TB drug-induced hepatotoxicity, which may necessitate discontinuation of treatment. [8] [9] [10] [11] Since TB and hepatitis B may co-exist in patients from endemic areas, some reports suggest to provide HBV testing to TB patients, which may improve TB management and treatment (through careful monitoring and treatment adjustment when necessary). 9, 11 Although hepatitis B may also impact patients with TB, there is currently very little data on HBV prevalence and risk factors among TB patients 8, 9, [11] [12] [13] [14] ; and no data are available regarding hepatitis B occult and HBV genotypes infecting these patients.
Objectives
This study aimed to assess the prevalence of HBV infection among TB patients with and without HIV in Goiânia City, Brazil. Occult hepatitis B, risk factors and HBV genotypes were also investigated.
Study design

Patients
This is a seroprevalence survey of TB patients for HBV with and without HIV in Goiânia City (estimated population of 1,300,000), the capital of the Goiás State in Brazil. All patients with clinical diagnosis of TB at out-patient and in-patient units at the Anuar Auad Hospital (the reference hospital for infectious diseases in Goiânia) were invited to participate in the study.
From April 2008 to March 2010, participants were recruited through physicians who explained the study objectives and procedures. After written informed consent was obtained from all participants, they were interviewed to collect data on sociodemographic, risk factors for HBV infection, and HBV vaccination status.
Participants were invited to receive HBV and HIV testing and were offered pre-test and post-test counseling. All seropositive patients were subsequently referred for medical follow-up and treatment was offered according to Brazilian guidelines. 15, 16 The protocol used for the present study was approved by the Ethical Committee of the Anuar Auad Tropical Disease Hospital, Goiânia, Goiás, Brazil.
Blood samples collection and serological tests
Blood was collected (10 ml) from all participants and serum samples were tested by enzyme-linked immunosorbent assay (ELISA) for the presence of HBsAg (Hepanostika HBsAg Ultra, Biomérieux, Boxtel, The Netherlands), antibodies to the total hepatitis B core antigen (anti-HBc) (Hepanostika anti-HBc Uniform, Biomérieux) and hepatitis B surface antibodies (anti-HBs) (Bioelisa anti-HBs, Biokit, Barcelona, Spain). HBsAg-positive samples were assayed for IgM anti-HBc (Bioelisa anti-HBc IgM, Biokit), hepatitis B e antigen (HBeAg) and antibody for HBeAg (anti-HBe) (Eti-Ab/Ebk Plus, Diasorin, Italy). Baseline serum samples were also tested by ELISA for anti-HIV-1.2.0 (Murex Biotech, Dartford, UK). HIV-positive samples were confirmed by Western blot (Bio Rad Laboratories, Marnes La Coquette, France).
PCR amplification and HBV genotyping
DNA was extracted from HBsAg and anti-HBc-positive samples. 17 The Pre-S/S genome region was amplified using a semi-nested PCR assay (detection limit of three copies of HBV DNA per reaction) and the amplicons genotyped by restriction fragment length polymorphism (RFLP) analysis. 18, 19 3.4. Quantification of HBV DNA HBV DNA-positive samples were quantified using the real-time PCR TaqMan technology, according to Pas and Niesters with some modifications. 20,21
Data analysis
Prevalence and 95% confidence intervals (95% CI) were calculated. The overall prevalence of HBV infection was defined by the presence of HBsAg and/or anti-HBc in serum. Potential risk factors for current or previous HBV infection (defined as positive for HBsAg and/or anti-HBc markers) were initially assessed by univariate analysis. Categorical variables were compared using Pearson's 2 test or Fisher's exact test. A p value ≤0.10 was used to select variables for inclusion in a multivariate logistic regression model. These variables are listed in Table 3 . A p value of <0.05 was defined as statistically significant. Data were analyzed using SPSS, version 11.0 (SPSS Inc., Chicago, US, 1999).
Results
A total of 425 TB patients were invited to take part in the study. Of these, 402 (94.6%) agreed to participate. Sociodemographic characteristics of the study population are shown in Table 1 . The mean age was 44.1 years (standard deviation = 15.6). Most patients were males (71.9%). Almost half of the study group (42.3%) was single, and 65.9% were non-Caucasian (most of them were Afro-Brazilian). Nearly 80.0% of the participants had received 9 years or less of formal education (fundamental education in Brazil) and 63.8% reported an income of US$300 or less.
As shown in Table 2 , 103 of the 402 patients (25.6%) had serological markers of current or previous HBV infection. Of these, 13 (3.2%) were HBsAg-positive, 9 were reactive for total anti-HBc only and 81 were anti-HBs and total anti-HBc-positive. In addition, 10.9% (44/402) of the study population were reactive for isolated antiHBs. One hundred and eleven patients (27.6%) were HIV-positive, 285 were HIV-negative and 6 had an undetermined HIV infection status. The overall prevalence of HBV infection among HIV-infected patients (36.9%; 41/111) was higher than in patients infected with TB only (20.0%; 57/285; 2 = 12.3, p < 0.01). However, HBsAg rates were similar in both groups (3.6% versus 3.1%; p > 0.05). Among the HBsAg-positive samples (n = 13), IgM anti-HBc marker was detected in four serum samples. In addition, the HBeAg and anti-HBe markers were found in two and eight samples, respectively. HBV DNA was detected in 10 (76.9%) HBsAgpositive samples. Of 81 total anti-HBc/anti-HBs reactive samples, 12 (14.8%) were HBV DNA-positive. Among the 9 total antiHBc only reactive samples, one (11.1%) was HBV DNA-positive. These results were confirmed by repeating both the DNA extraction and amplification procedures, thereby establishing the occult HBV infection rate at 14.4% (13/90) among total anti-HBc-positive TB patients. As expected, HBV DNA levels were significantly lower in patients with occult infection (range: 1.7 × 10 2 to 6.7 × 10 2 copies/ml, mean: 3.3 × 10 2 copies/ml) compared to those who were HBsAg-positive (range: 6.9 × 10 3 to 2.4 × 10 8 copies/ml, mean: 2.5 × 10 7 copies/ml). PCR-RFLP was successfully performed in 20 HBV DNA-positive samples, with isolates belonging to the HBV genotypes A (n = 15) and D (n = 5).
Univariate analysis of risk factors for HBV infection revealed that male gender, injecting drug use and alcohol consumption were associated with this infection. In a multivariate analysis, age ≥50 years (p = 0.03), non-injecting (p < 0.01) and injecting (p < 0.01) drugs use were independent risk factors associated with HBV infection (Table 3) .
Discussion
The overall prevalence of HBV infection found among TB patients was higher than those reported in other Brazilian populations such as individuals reporting to an HIV Testing and Counseling Center (14.6%; 95% CI: 11.2-18), 22 patients attending a Sexually Transmitted Diseases Clinic (13%; 95% CI: 10.0-16.5) and noninjecting drug users (14%; 95% CI: 11.7-16.5). 23, 24 The prevalence determined in this study was within the confidence interval range reported for injecting drug users (27.1%; 95% CI: 23.6-30.8) and hemodialysis patients (29.8%; 95% CI: 27.1-32.5). 25, 26 Relative to other data reported in TB patients, the HBV prevalence determined in this study was similar to prevalence rates observed in Rio de Janeiro, Brazil (26.8%; 95% CI: 19.7-31.9) and Argentina (19.8%; 95% CI: 14.3-26.2), 12,13 but was higher than rates determined in Georgia (13%; 95% CI: 9.5-17.5) and Taiwan (11.7%; 95% CI: 6.8-15.5). 9, 11 The high prevalence rates of HBV infection found in TB/HIVinfected patients and in patients with TB only were similar to those observed in Rio de Janeiro (35.8% and 14.6%, respectively). 12 Other studies have indicated that HBV and HIV infections have been found to increase the risk of anti-TB drug-induced hepatotoxicity that may necessitate discontinuation of treatment. [8] [9] [10] [11] Among the HBV infected patients, two developed hepatotoxicity: one patient during the first month of TB treatment (HBsAg/HBeAg-positive and had a high HBV DNA level: 6.7 × 10 6 copies/ml), while the other patient during the second month of TB treatment (had occult HBV infection with HBV DNA level of 1.9 × 10 2 copies/ml). In both cases, TB treatment adjustment was necessary (data not shown).
In the present study, age ≥50 years was associated with HBV infection, which was consistent with another study characterizing TB patients in Argentina. 13 Age may be a proxy for lifetime exposure, indicating that, over time, there is a cumulative risk of HBV infection linked to sexual and percutaneous exposures. In fact, injecting drug use was an independent risk factor for HBV infection in the study population described in this report. This behavior has been reported by others among TB patients, 9,13 reflecting the high transmissibility of HBV through direct blood contact resulting from the sharing of syringes and needles. In addition, non-injecting drug use was statistically associated with HBV infection in the study population described here, which was probably linked to percutaneous exposures related to sharing of non-injection drug implements such as pipes and straws for smoking and sniffing/snorting, which could lead to blood-to-blood contact. These behaviors have been suggested by others to lead to the HBV exposure by non-injecting drug users. 27 The present study provides the first set of data describing the prevalence of occult HBV infection in TB patients. Although no similar reports are available for direct comparison, the proportion of occult HBV infection among the anti-HBc-positive patients identified was similar to that reported in HIV infected patients in Brazil (14%), 28 but higher than that observed in Brazilian blood donors (4%). 29 The HBV genotypes A (n = 15) and D (n = 5) identified in the HBV DNA-positive TB patients were in accordance with data reported in other populations in Brazil where genotype A predominated, followed by genotype D. 19, 21, 24, 26, 30 Only 44 (10.9%) TB patients were reactive for isolated antiHBs, suggesting that they had been vaccinated for HBV. In fact, all of them self-reported an HBV vaccination (38 had received three doses and the remaining two doses). In Brazil, the National Immunization Program recommends administration of the hepatitis B vaccine for newborns, children and young adults under 24 years of age, as well as for high-risk individuals but not for TB patients.
TB control remains a great challenge for public health globally. 6 Hepatotoxicity development during anti-TB treatment is the most important adverse event, and could result in low treatment success. [8] [9] [10] [11] Although the incidence of hepatotoxicity during TB treatment is outside the scope of this cross-sectional study, it was possible to identify two HBV infected patients who developed hepatotoxicity during TB treatment. Therefore, further clinical prospective studies with a close follow-up of HBV/TB and HBV/HIV/TB co-infected patients are necessary and, thus, optimize the management of these important infections.
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